Archive for the ‘behind a paywall’ Category
It began with a retraction due to a “misstatement” in November 2012, which led to an investigation that found the first author, James E. Hunton, guilty of misconduct. Now, the floodgates have opened, and Hunton has 31 retractions under his belt, making him the newest addition to the Retraction Watch leaderboard.
A month after the first retraction in 2012, Hunton resigned from his accounting professorship at Bentley University, citing family and health concerns.
Then, in 2014, a university investigation concluded that Hunton fabricated data in two papers and may have destroyed evidence. The first paper was the one retracted from Accounting Review for a misstatement; the second was retracted from Contemporary Accounting Research in December 2014. Even though the investigation centered around two publications, the university suggested more may be affected:
They realized their mistake soon after the article, “RNA transcripts of full-length cDNA clones of rabbit hepatitis E virus are infectious in rabbits,” was published online in the Journal of General Virology in November, 2014. They withdrew the article before it made it into print.
The article came from a group led by Xiang-Jin Meng, of the Virginia-Maryland College of Veterinary Medicine, an offshoot of Virginia Tech and the University of Maryland.
As every mushroom lover knows, weekend mycology is no sport for the lily-livered. Tasty species often look awfully like their deadly cousins. Turns out, typing can even be problematic for the experts.
The paper, “Chemical constituents: water-soluble vitamins, free amino acids and sugar profile from Ganoderma adspersum,” was written by Ibrahim Kivrak, a food chemist at Mugla Sitki Kocman University in Mugla, Turkey. It analyzed the nutritional components of G. adspersum, and found, per the abstract:
The Journal of Immunology is retracting a 2006 article about the role of exosomes in pregnancy at the behest of the University of Louisville in Kentucky, following a misconduct investigation that “determined multiple figures” in the paper were falsified.
The retracted paper identified “significant quantitative and qualitative differences in released exosomes” in the placentas of fetuses delivered prematurely compared to those delivered without complications at term, particularly relating to immune regulation. It has been cited 150 times, according to Thomson Scientific’s Web of Knowledge.
The paper, “N, S co-doped graphene quantum dots from a single source precursor used for photodynamic cancer therapy under two-photon excitation,” was ostensibly written by nine researchers at the Collaborative Innovation Center for Marine Biomass Fiber, Materials and Textiles of Shandong Province, the Shandong Sino-Japanese Center for Collaborative Research of Carbon Nanomaterials, Laboratory of Fiber Materials and Modern Textiles, the Growing Base for State Key Laboratory at the College of Chemical Science and Engineering at Qingdao University, and Mayo Clinic, in Rochester, Minn.
A highly cited study examining the risks of heart disease in post-menopausal women with symptoms of polycystic ovary syndrome (PCOS) has been retracted by its authors because they could not replicate the results.
These two new retractions, in Genes and Development, stem directly from another paper by Weinberg and colleagues in Cell that will apparently be retracted, as the “same analytical methodology was used,” according to the notices [see bottom of the post for an update].
Weinberg is highly regarded, and at least 20 of his papers have been cited over a thousand times.
First author Scott Valastyan was a promising postdoc at the time of the paper’s publication. He was a 2011 Runyon Fellow at Harvard, a three-year, $156,000 award for outstanding cancer postdocs. He doesn’t seem to have published anything since 2012, though he is listed as a joint inventor with Weinberg on patents filed in 2009 and 2014.
Here are the notices for “Concomitant suppression of three target genes can explain the impact of a microRNA on metastasis” (cited 73 times, according to Thomson Scientific’s Web of Knowledge) and “Activation of miR-31 function in already-established metastases elicits metastatic regression” (cited 54 times), both paywalled: Read the rest of this entry »
According to the Process Safety and Environmental Protection retraction notice, the 2013 paper, by a group at Tsinghua University in Beijing, plagiarized part of a 2007 article by Greek researchers called “Modeling emergency evacuation for major hazard industrial sites.” (The 2007 article has been cited 46 times, according to Google Scholar.)
Here’s the notice for “Emergency Response Plans Optimization for Unexpected Environmental Pollution Incidents using an Open Space Emergency Evacuation Model” (paywalled): Read the rest of this entry »
The authors of a 2007 PNAS paper that provided molecular details for how calorie restriction may act on Sir2 enzymes to extend life are now retracting their research after discovering a figure was compromised by “several unintentional anomalies in the background image.”
According to study author David W. Piston at Vanderbilt University, first author Qinghong Zhang cut and pasted images together to beautify a figure showing how a form of sugar affects the expression of SIRT1, the mammalian version of the Sir2 enzyme: Read the rest of this entry »
According to the notice, the corresponding author, David Shima, now at University College London, brought his concern to the journal. He called it a “genuine error” and stated that all the findings had been reproduced.
Unfortunately, Shima claimed the original data are missing, because the institution that owned the information — Eyetech Research Center — has “since gone through several acquisitions.”
Ocular neovascularization occurs when growth signals in the eye stimulate the creation of many new blood vessels. Over time these blood vessels break, causing bleeding and scarring that limits vision. This is called “wet” macular degeneration.
The scientists found that giving patients drugs to limit two different growth factors at the same time is more effective than one at stopping the progression of AMD. This combination method is in stage three clinical trials, though with different drugs than the authors used here.
The paper, published in 2006, has been cited 130 times, according to Thomson Scientific’s Web of Knowledge. Here’s the EoC for “Inhibition of Platelet-Derived Growth Factor B Signaling Enhances the Efficacy of Anti-Vascular Endothelial Growth Factor Therapy in Multiple Models of Ocular Neovascularization”: